The Report
Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses
41 reports and counting
Candid Raises $200M in Series D
Candid, a AI/ML company based in San Francisco, CA, has raised $200M in Series D at a $1.5B valuation led by General Catalyst, Index Ventures.
Candid raises $200M Series D at $1.5B valuation
Candid raises $200M in Series D at $1.5B valuation. AI for business intelligence...
Candid Therapeutics Raises $370M in Series A
Candid Therapeutics, a Biotech company based in San Francisco, CA, has raised $370M in Series A at a $1.2B valuation led by Venrock, Fairmount, TCGX.
Candid Therapeutics raises $370M Series A at $1.2B valuation
Candid Therapeutics raises $370M in Series A at $1.2B valuation. Developing novel therapeutics for autoimmune diseases...
BioPharmaceuticals Next Secures $1.6B Series E to Lead Pharmaceuticals Innovation
BioPharmaceuticals Next raises $1.6B in Series E funding at $24.3B valuation to advance 12 drug candidates through clinical trials, scale gene therapy manufacturing, and expand personalized medicine programs.
Octant Bio Raises $175M Series B
Drug discovery company using high-throughput screening and machine learning to identify novel therapeutic targets and drug candidates
Treeline Biosciences Raises $421 Million in Undisclosed Round - October 17, 2024
Treeline Biosciences announced $421 Million in Undisclosed Round funding at a $1.1 Billion+ Total Raised valuation. Treeline Biosciences is a secretive biotech company focused on developing innovative cancer therapeutics using AI-powered drug discovery platforms....
Jack & Jill Raises $20M in Series A
Jack & Jill, a SaaS company based in Austin, TX, has raised $20M in Series A at a $75M valuation led by Craft Ventures, Spark Capital.
SciNeuro Raises $53 million in Series B
SciNeuro, a Biotechnology company based in Shanghai China, has raised $53 million in Series B at a Undisclosed led by Chinese.
Showing 9 reports β’ Page 1 β’ Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.